Agios Announces Results From Phase 3 ACTIVATE-KidsT Study Of Mitapivat In Children With PK Deficiency Who Are Regularly Transfused; Says Prespecified Statistical Criterion For Primary Endpoint In ACTIVATE-KidsT Was Not Met
Portfolio Pulse from Benzinga Newsdesk
Agios Pharmaceuticals announced that the Phase 3 ACTIVATE-KidsT study of Mitapivat in children with PK deficiency who are regularly transfused did not meet the prespecified statistical criterion for the primary endpoint.
August 01, 2024 | 10:34 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Agios Pharmaceuticals' Phase 3 ACTIVATE-KidsT study of Mitapivat in children with PK deficiency did not meet the prespecified statistical criterion for the primary endpoint, which could negatively impact investor sentiment and the stock price in the short term.
The failure to meet the primary endpoint in a Phase 3 study is a significant setback for any pharmaceutical company, as it can delay the approval process and reduce investor confidence. This news is likely to result in a short-term decline in Agios Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100